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INHIBITION OF VASCULAR PERMEABILITY BY SEMAPHORIN 3F IN 
ACUTE INFLAMMATION 
DAVID LI 
ABSTRACT 
 Edema or tissue swelling is exacerbated during inflammation due to increased 
leukocyte infiltration and vascular permeability, after which resolution returns the tissue 
to homeostasis. In acute inflammatory reactions, upregulated levels of vascular 
endothelial growth factor (VEGF) is shown to increase vascular permeability. Vascular 
endothelial cells (EC) form a selective barrier regulating the degree of microvascular 
exchange and permeability in normal physiological and pathological settings. Vascular 
EC express pro-permeability VEGF receptors and neuropilin co-receptors that can 
mediate both stimulatory and inhibitory signals. Secreted class 3 semaphorin-3F 
(SEMA3F) is a high affinity ligand for the NRP2 receptor and has been shown to be anti-
angiogenic through its ability to inhibit cell migration and attachment. Importantly, 
SEMA3F has been shown to compete for binding with VEGF to the NRP2 receptor. 
However, the role, if any, of SEMA3F in inflammation has yet to be fully elucidated. 
We hypothesize that SEMA3F reduces edema by inhibiting vascular permeability 
thereby promoting a quickened resolution of inflammation. To generate inflammatory 
lesions, delayed-type hypersensitivity cutaneous reactions were induced on the ear skin of 
C57BL/6 mice through topical applications of oxazolone. Total ear thickness as a readout 
of tissue swelling was compared to baseline (Day 0). To determine the effects of 
depleting SEMA3F during inflammation, ear thickness was measured after SEMA3F 
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antibody or control IgG intraperitoneal injection into Nrp2+/- mice. To assess the effects 
of increased systemic SEMA3F on edema, ear thickness was measured after intravenous 
delivery of SEMA3F adenovirus (Ad-3F) or control adenovirus into wild-type mice.  
We report that SEMA3F depletion via SEMA3F antibodies led to significantly 
prolonged edema compared to controls. Ad-3F treated mice exhibit lower levels of 
inflammatory edema compared to control. We demonstrate that the SEMA3F signaling 
cascade is a key mediator of fluid homeostasis in inflammation. Likely, SEMA3F serves 
as an anti-inflammatory mechanism preventing excessive edema. 
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INTRODUCTION 
 
 The Developing Vasculature  
The vascular network including the heart is the first organ to arise during 
development (Risau 1998). Vessels form and penetrate every organ of the body, ensuring 
adequate nutrient delivery, oxygen homeostasis, and waste removal (Semenza 2007). 
During embryogenesis, de novo blood vessel formation from endothelial progenitors 
(vasculogenesis) is coupled to a tightly regulated series of coordinated migratory, growth, 
and sprouting events. These events give rise to new vessels from preexisting ones that 
grow and develop further until the final culmination of a fully mature vasculature 
(Carmeliet 2003; Heil et al. 2006; Semenza 2007). Postnatally, these neovascularization 
events are recapitulated in many physiological and pathological processes (Gale et al. 
2002; Isner and Asahara 1999; Ogunshola et al. 2000; Potente et al. 2005).  
Endothelial cells (EC) are critical in forming the endothelium and establishing a 
mature vascular network. The vascular endothelium is a monolayer of endothelial cells 
lining the interior of the body’s vasculature forming an interface between the vessel 
lumen and wall (Yuan and Rigor 2010). These cells are long, thin cells with a half-life of 
a few years and are, through their mechano- and bio-sensory capabilities, the key 
regulators in maintaining vascular homeostasis (Carmeliet 2003; Chien 2007). 
Endothelial cells are also heterogeneous in nature. They can vary between different 
organs, different segments of the vasculature in the same organ, and even between 
neighboring cells (Aird 2007; Risau 1998). These vascular cells are shown to be integral 
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in barrier function, blood clotting, inflammation, angiogenesis, modulating blood 
pressure, etc. (Anand et al. 2010; Fukumura et al. 2001; Pober and Sessa 2007). 
Endothelial Cell Barrier Integrity 
The resting endothelium 
 Under normal physiological conditions, vascular endothelial cells participate in 
maintaining blood flow, vessel-wall permeability, promoting quiescence in circulating 
leukocytes and overall vascular homeostasis (Pober and Sessa 2007). To maintain blood 
fluidity, the endothelial cells express tissue factor pathway inhibitors that prevent the 
initiation of the coagulation pathway. Endothelial cells produce nitric oxide (NO) and 
prostacyclin which help prevent platelet activation and aggregation and promote healthy 
blood flow (Frangos et al. 1985; Pober and Sessa 2007; Sessa 2004). Plasma proteins are 
mostly prevented from extravasating into the tissues by the endothelial cell lining of the 
vascular capillaries. In addition, quiescent endothelial cells inhibit expression of 
leukocyte-interacting proteins such as selectins (E-selectin, P-selectin, etc.), chemokines, 
and leukocyte adhesion molecules (VCAM1, ICAM1, etc.) (Butcher 1991; Granger and 
Kubes 1994; Middleton et al. 2002). Furthermore, basal levels of endothelial NO 
production serve to inhibit adhesion molecule expression and cytokine/chemokine 
synthesis (Salvemini, Ischiropoulos, and Cuzzocrea 2003) while disturbed blood flow has 
been shown to be a symptom of EC dysfunction and renders them more prone to 
inflammation and injury (Chiu and Chien 2011).  
Cell-cell junctions in barrier maintenance 
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 Endothelium integrity is maintained by intercellular junctions and is critical in 
regulating the flow of solute between the vasculature and the extravascular space. The 
paracellular pathway of solute transport is primarily facilitated by the coordinated 
opening and closing of endothelial cell-cell junctions (Dejana, Orsenigo, and 
Lampugnani 2008). This process involves a complex rearrangement process of adhesion 
proteins and cytoskeletal structures (Cavallaro and Dejana 2011; Weis and Cheresh 
2005). Adhesion molecules linked to cytoskeletal structures are expressed at endothelial-
cell junctions. These proteins are expressed in adherens junctions and tight junctions. 
Adherens junctions between cells serve to maintain cell shape and integrity and support 
the localization of scaffolding and signaling molecules (Maria Grazia Lampugnani 2010). 
Tight junctions have also been implicated in the regulation of endothelial paracellular 
trafficking, albeit to a lesser extent. The proteins that form tight junctions include 
occludins, claudins, junctional adhesion molecules, and many others. In the brain 
capillary endothelial cells, Claudin-5 has been shown to be significantly expressed at 
tight junctions (Günzel and Yu 2013). In addition, mitogen-activated protein kinases have 
been linked to occluding dissociation in response to the presence of hydrogen peroxide 
and radicals (Alexander and Elrod 2002; Kevil et al. 2000).   
The cadherin family of adhesion protein receptors is involved in the formation of 
cell-cell bridges which form adherens junctions. Endothelial cells highly express two 
types of cadherins: endothelial-cell-specific VE-cadherin (vascular endothelial cadherin) 
and non-cell-type-specific N-cadherin (neuronal cadherin). Other types of cadherins (T-
cadherin, P-cadherin, etc.) are expressed but at lower levels. VE-cadherin is a 
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transmembrane protein highly clustered at adherens junctions that possesses a 
cytoplasmic tail linked to associated intracellular catenins and other actin-binding 
elements to form a complex (Figure 2). This cadherin complex affects and is affected by 
the actin cytoskeleton. The reorganization of the actin at these junctional nodes can be 
regulated by the GTPases Rac and Rho. Rho can also affect the contractility of the 
actomyosin stress fibers, a complex of both actin and myosin (Maria Grazia Lampugnani 
2010). While this complex has been shown to affect cell morphology, changes in cell 
morphology are not required for changes in permeability. For example, internalization of 
the VE-cadherin complex or phosphorylation of other adhesion molecules can induce 
weakness in the gap junctions without affecting cell morphology (Benn et al. 2016). 
Antibodies generated to the extracellular domain of VE-cadherin have been shown to 
induce permeability (Gotsch et al. 1997). In addition, vascular endothelial growth factor 
(VEGF) –dependent and –independent increases in permeability, to a lesser extent 
compared to the antibody treatment, has been shown to affect VE-cadherin binding 
functions (Benn et al. 2016).  
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Figure 1 | The molecular organization of VE-cadherin. VE-cadherin is a dimer which 
forms functional units when complexed with intracellular catenins and other actin-
binding factors. Signal transduction through this complex can affect endothelial cell 
structure and shape thereby impacting the leakiness of endothelial cell-cell junctions. 
Adapted from Dejana et al. (2008). 
 
Endothelial cell-extracellular matrix interactions 
Integrin interaction of endothelial cells with the extracellular matrix can also 
influence the integrity of the endothelial barrier. Integrins are a family of transmembrane 
cell adhesion receptors for extracellular matrix proteins that interact with cytoskeletal 
proteins such as actin, vinculin, talin, etc. Integrins are heterodimeric proteins composed 
of alpha and beta subunits. Endothelial cells express multiple types of integrins 
implicated in focal adhesion formation, cell adhesion and spreading, and other 
biochemical signaling events (Oguey, George, and Rüegg 2000). Importantly, endothelial 
cells express integrins critical for adhesion via proteins abundant in the extracellular 
matrix such as laminin, collagen, and fibronectin (M. G. Lampugnani et al. 1991). For 
example, in cultured human umbilical vein endothelial cells monolayers, integrins 
heterodimers alpha2-beta1 and alpha5-beta1 are shown to play a role in maintaining EC 
monolayer integrity. Antibody neutralization of alpha5-beta1 showed increased 
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permeability of the EC monolayers (M. G. Lampugnani et al. 1991). It has been reported 
that integrin receptor binding to the extracellular matrix can stabilize the endothelial cell 
barrier by stabilizing junction integrity. Integrins have also been implicated in 
permeability generated from inflammatory mediators such as thrombin, bradykinin, 
histamine, vascular endothelial growth factor, etc. (Mehta and Malik 2006). 
Vascular Permeability 
The vascular endothelium needs to be sufficiently permeable to allow for the 
exchange of molecules (gas, nutrients, waste, plasma proteins) but still regulated enough 
to prevent excessive leakage. The regulation of vascular permeability is critical in normal 
tissue homeostasis. There are three types of vascular permeability (Nagy et al. 2008) 
classified by: 
1. The nature of the microvessel composition: continuous, fenestrated, or 
sinusoidal  
2. The composition of the extravasate: protein rich or protein poor 
3. The type of pathway by which molecules cross the endothelium: paracellular or 
transcellular 
The degree of microvascular exchange derives from the integrity of the 
endothelial structure, maintained through tight cell-to-cell junctions under the control of 
growth factors, cytokines, and other inflammation related molecules. The expression of 
transmembrane adhesion proteins (VE-cadherin, N-cadherin, occludins, and other cell 
adhesion molecules) contribute to the maintenance of EC barrier integrity and function. 
The size-selective nature of the endothelium serves as a barrier to plasma proteins and is 
 7 
key in establishing protein gradients to maintain fluid balance between vasculature and 
interstitium (Mehta and Malik 2006). The selective permeability of the endothelium is 
correlated with molecular radii. Molecules with radii from 0.1nm to 3.6nm such as ions 
and water mainly pass through the endothelium paracellularly through interendothelial 
junctions. Molecules with radii > 3.6 nm such as plasma albumin or immunoglobulin 
(IgG) traverse the endothelium through transcellular pathways using transcytosis or 
vesicular transport (Sukriti et al. 2014). However, both cellular transport pathways are 
integral in maintaining the multiple functions of the endothelium. 
Under normal physiological conditions, the junctions allow for the passage of 
small molecules and various inflammatory cells. However, the degree of permeability of 
the endothelium varies in different tissues. The coronary, pulmonary, and splanchnic 
vascular beds are composed of continuous non-fenestrated endothelial cells. The liver, 
lymphatics, and kidney however, are made up of discontinuous and highly permeable 
endothelial monolayers (Sukriti et al. 2014).  Basal levels of permeability might change 
(e.g. during exercise), but it is necessary to distinguish basal levels of permeability with 
the increased levels of permeability due to disease pathologies. The exudate composition 
in basal levels of permeability compared to acute/chronic vascular hyperpermeability 
differ considerably. Specifically, the molecular exchange process during basal levels of 
permeability is mainly passive and through diffusion and usually plasma-protein poor. 
However, under increased levels of permeability, the exudate becomes protein rich, 
primarily composed of albumin. Albumin, the most abundant plasma protein serves as 
circulating chaperones for fatty acids, hormones, and water-insoluble substances crucial 
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for interstitial cell functions. Therefore, there exists a requirement for continuous 
transendothelial protein flux or basal levels of vascular permeability; however, this 
dynamic process must be closely regulated to prevent excessive protein efflux (Mehta 
and Malik 2006). Under normal physiological conditions, albumin flux across the 
endothelial barrier derives from the balance between vascular hydrostatic and oncotic 
pressure, interstitial hydrostatic and oncotic pressure, and endothelial permeability.  
Under an inflammatory stimulus, the endothelium is compromised, leading to an 
increased efflux of plasma into the surrounding tissue (Mehta and Malik 2006; Yuan and 
Rigor 2010). This plasma efflux often contains a mixture of inflammatory cells, 
fibrinogen, proteins, etc. Increased vascular permeability is characteristic in many 
biological responses and disease states such as in acute inflammation and tumor-
associated angiogenesis (Cavallaro and Dejana 2011). Acute vascular hyperpermeability 
occurs after brief exposure to vascular pro-permeability agents, while chronic vascular 
hyperpermeability is associated with chronic exposure to vascular pro-permeability 
agents, often leading to angiogenesis, lymphangiogenesis, and vascular remodeling 
(Nagy et al. 2008). Uncontrolled vascular permeability that is not balanced by lymphatic 
fluid drainage can lead to edema, increasing the risk of developing ischemic tissue injury 
(Dejana, Orsenigo, and Lampugnani 2008; Weis and Cheresh 2005).  
Fluid homeostasis and edema formation 
While a certain degree of vascular leakage is necessary, excessive leakiness can 
produce excessive tissue swelling or edema that promotes undesirable movement of cells, 
metastasis of cancer, etc. (Scallan, Huxley, and Korthuis 2010). Edema occurs as a 
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consequence of over-accumulation of fluid in the tissue, either within the collagen 
(interstitial edema) or within cells (cellular edema) (Liang et al. 2007; Scallan, Huxley, 
and Korthuis 2010). Cytotoxic cellular swelling is usually the result of abnormal channel-
mediated influx of ions into the intracellular space leading to cell death and depletion of 
ions from the microenvironment (Zakaria et al. 2007).  
Edema is considered detrimental to tissue function because of the increase in 
diffusion distance preventing efficient transfer of oxygen and nutrients (Kalogeris et al. 
2016). Similarly, edema can hinder the removal of toxic byproducts of cellular 
metabolism (Scallan, Huxley, and Korthuis 2010). Small increases in interstitial pressure 
due to fluid accumulation can be extremely detrimental to some tissues, such as those 
encapsulated by tight fascial sheaths e.g. kidney, brain, etc. As mentioned above, edema 
can be caused by excessive hydrostatic pressure producing an accumulation of interstitial 
fluid (hydrostatic), disruptions in the microvascular membrane, or impaired lymphatic 
drainage function (lymphedema). During inflammation, extracellular matrix proteins are 
broken down by enzymes produced by infiltrating leukocytes, resident cells, and other 
cells in the parenchyma (Ley et al. 2007; Parks, Wilson, and López-Boado 2004). This 
can alter the compliance characteristics of the interstitium such that fluid dynamics 
become disrupted. For example, the destruction of extracellular matrix proteins can 
reduce the tensional forces that anchor lymphatic endothelial cells thereby reducing the 
mechanical stability of the lymphatic network (Scallan, Huxley, and Korthuis 2010; 
Stratman et al. 2009). The organization and composition of the extracellular matrix 
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determines the mechanical properties of the interstitium which impact the fluid dynamics 
of edema formation and drainage. 
Delayed Hypersensitivity Reactions 
The skin is the largest organ in the mammalian body and aids in protecting the 
host from the environment (S. Y. Park et al. 2011). Besides forming a physical barrier, 
the skin also helps maintain the homeostatic balance between pro- and anti-inflammatory 
responses. The immune response is divided into antibody-mediated responses (humoral 
immunity) and cell-mediated responses (cell-mediated immunity). Cell-mediated 
immunity consists of many distinct types of responses, one of which is the delayed-type 
hypersensitivity (DTH) response (Huber et al. 1976). Delayed hypersensitivity is a Th1-
cell mediated immune response in which activated T cells initiate a cascade of immune 
responses that lead to the generation of erythematous and indurated lesions such as in the 
case of contact dermatitis. DTH reactions often are separated into two phases: 1) 
Sensitization phase – referring to the initial immune encounter to a specific antigen and 2) 
Challenge phase – referring to the DTH response after sensitization (Yi Luo and Dorf 
2001). During DTH reactions there is an increased amount of fibronectin deposits due to 
increased plasma extravasation and local vessel wall synthesis which helps encourage 
cell migration and macrophage activation (Brown et al. 1995; Clark, Dvorak, and Colvin 
1981). Also, polymorphonuclear leukocytes play an important role in the pathogenesis of 
certain delayed hypersensitivity diseases e.g. Crohn’s disease, psoriasis, rheumatoid 
arthritis, etc. due to the phenotype of the infiltrating T-cells and also the local resident 
cells (Biedermann et al. 2000). However, DTH reactions can also exhibit heterogeneity. 
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For instance, IL-4 is strongly expressed in allergic contact dermatitis lesions, while IFN-
gamma is the main cytokine expressed in tuberculin reactions (Ohmen et al. 1995). It was 
shown that both macrophages and T-cells are required for the development of a full DTH 
response, primarily through their production of tumor necrosis factor (TNF) and 
chemokines (Biedermann et al. 2000). These secreted factors facilitate the attachment and 
migration of polymorphonuclear leukocytes into the sites of inflammation. In addition, 
microvascular hyperpermeability is a typical feature of DTH (Brown et al. 1995), most 
likely due to upregulated VEGF production from epidermal keratinocytes and infiltrating 
leukocytes (Brown et al. 1995). It’s also been shown that this hyperpermeability works 
through a histamine-independent pathway, although large amounts of histamine are 
present but not released inside cutaneous mast cells and infiltrating basophils during DTH 
(Goldman, Simpson, and Dvorak 1973).  
Vascular Endothelial Growth Factor (VEGF) & VEGF receptor  
 Vascular endothelial growth factor (VEGF) has been discovered to be a heparin 
binding angiogenic, pro-permeability growth factor for vascular endothelial cells (Senger 
et al. 1983). During development, VEGF is the major regulator of vasculogenesis, 
angiogenesis, and the formation of the vascular network (Neufeld et al. 1999). Pro-
permeability factors such as VEGF and platelet-derived growth factor can disorganize the 
junctional proteins, leading to an increase in endothelial permeability (Sukriti et al. 
2014). VEGF is the canonical regulator of angiogenesis, vasculogenesis, and vascular 
permeability (Soker et al. 1998). It has been shown to be a critical regulator of 
physiological angiogenesis, regulating new vessel development and maturation (Ferrara, 
 12 
Gerber, and LeCouter 2003). Vascular endothelial growth factors (VEGFs) and their 
associated receptors (VEGFR 1-3) were originally thought to be as an endothelial cell 
specific mitogens but now many cell types including tumor cells, macrophages, platelets, 
keratinocytes, neurons, etc. are known to secrete or respond to VEGF (Harmey et al. 
1998; Man et al. 2006; Song, Gong, and Wu 2002; Verheul et al. 1997).  
The mammalian VEGF family consists of five members: VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and placenta growth factor (PGF). VEGF-A is made up of eight 
exons and can be alternatively spliced to produce many isoforms: VEGF121, VEGF165, 
VEGF189, and VEGF206. The VEGF-A (or sometimes simply referred to as VEGF) 
isoforms VEGF165 and VEGF121 are the most predominant due to bioavailability and 
effectiveness (Ferrara, Gerber, and LeCouter 2003).  VEGF-A can be secreted from 
normal tissues and from tumor cells where it can circulate in the blood, and bind to 
endothelial cell VEGFRs (Neufeld et al. 1999).  
VEGF-A binds and activates both VEGFR-1 and VEGFR-2 (main mediator) and 
has been implicated in angiogenesis, vascular permeability, cell migration, etc. Of note, 
VEGF-A is significantly upregulated under hypoxic conditions via increased stabilization 
of VEGF-A promoter elements. Binding of VEGF-A to VEGFR-2 on endothelial cells 
can lead to receptor dimerization and autophosphorylation of VEGFR-2, thereby 
activating multiple downstream signaling pathways involved in filopodial extension, 
proliferation, etc. (Olsson et al. 2006a). Interestingly, VEGF-A has higher affinity to 
VEGFR-1 but there seems to be less observed effects of VEGFR-1 activation in the adult 
compared to VEGFR-2. The current hypothesis is that VEGFR-1 might act as a decoy 
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receptor, sequestering VEGFA and preventing VEGFR-2 over activity (J. E. Park et al. 
1994). VEGF-B is a ligand for VEGFR-1 that is not critical for embryonic vascular 
development. Moreover, VEGF-B seems to upregulate vascular pro-survival genes and 
may act as a “survival” promoting factor (F. Zhang et al. 2009). VEGF-C and VEGF-D 
are initially produced in premature forms and then cleaved by proteases to become active 
and exhibit high affinity for VEGFR-3. They possess weak affinity for VEGFR2 but will 
nonetheless bind and have been shown to be angiogenic to a certain degree. However, the 
role of VEGF-C and VEGFR-3, in particular, has been implicated in lymphangiogenesis. 
VEGF-C overexpression in breast cancer cells is shown to increase lymphangiogenesis 
(Skobe et al. 2001).  
Proteolysis and alternative splicing is important in regulating VEGF protein 
function. Through these events, different isoforms of VEGF-A with vastly different 
biological properties can be generated (Ferrara 2010). For example, proteolytic cleavage 
by plasmin of VEGF-A at the carboxyl terminus can give rise to the biologically active 
VEGFA110 isoform (Ferrara 2010; Gutierrez et al. 2008; Lowe et al. 2007). It is well 
documented that VEGFA165 is normally implicated in physiological and pathological 
angiogenesis (Varey et al. 2008). However, VEGFA165b generated from alternative 
splicing has been shown to be present in normal cells and tissues and possesses anti-
angiogenic effects (Varey et al. 2008).  
VEGF receptors 
VEGFRs are tyrosine kinase receptors (RTKs) that possess an extracellular 
domain for ligand binding, a transmembrane domain, and a cytoplasmic tyrosine kinase 
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domain. (Huang et al. 2013). VEGFR-1, VEGFR-2, VEGFR-3 can bind different forms 
of VEGF in overlapping fashion (Figure 2). VEGFRs are mostly expressed in the 
vascular system, however studies have also shown VEGFR expression on non-
endothelial cells (Man et al. 2006). VEGFR-2 expression can be seen in neural and retinal 
cells; however it is primarily expressed in EC. VEGFR-2 has been shown to influence EC 
survival, migration, proliferation, and permeability.  
The activity of RTKs are heavily governed by the availability and concentration 
of their ligands (Olsson et al. 2006b). VEGFRs are able to form homodimers and 
heterodimers under ligand influences (Dixelius et al. 2003). The dimerization of these 
receptors is coupled with activation of receptor-kinases that leads to autophosphorylation 
which subsequently induces recruitment of interacting proteins that activate multiple 
secondary messengers (Olsson et al. 2006c). The internalization of RTKs is important for 
preventing excessive responses from ligand activation. It has been shown that 
phosphorylation of VEGFR-2 is subsequently quickly dephosphorylated by tyrosine-
specific phosphatases Src-homology phosphatase-1 (SHP1) and Src-homology 
phosphatase-1 (SHP2) (Gallicchio et al. 2005; Guo et al. 2000). Furthermore, regulated 
endocytosis of the VEGFRs is critical for quick and precise localized responses to VEGF 
gradients (Gaengel and Betsholtz 2013). In the case of VEGFR-2 internalization and 
degradation, it is shown that this pathway is mediated by protein kinase C 
phosphorylation of the C-terminal tail (Singh et al. 2005) and clathrin-mediated 
endocytosis through epsin endocytic adaptor proteins (Tessneer et al. 2014). 
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Figure 2 | VEGF binding specificity to VEGF receptors. VEGF family members and 
their respective high-affinity binding VEGF receptors are shown. The VEGFRs contain 
seven immunoglobulin-like binding domains in the extracellular region and a tyrosine 
kinase domain in the intracellular region. Adapted from Ruiz de Almodovar et al. (2009). 
 
VEGF-A and vascular permeability 
VEGF-A was initially characterized as vascular permeability factor from tumor-
promoted accumulated ascites (Senger et al. 1983). Research has shown that 
VEGF-A can increase permeability in a number of ways such as increasing the 
production of endothelial nitric oxide synthetase (Fukumura et al. 2001), 
activating Src and tyrosine-protein kinase Yes signaling integral in cell-to-cell 
contacts (Eliceiri et al. 1999), and also regulating VE-cadherin (Gavard and 
Gutkind 2006). The mechanisms of VEGF-A induced vascular permeability are 
also due to the formation of small fenestrations in the EC which allow for 
transcellular transport through vesiculo-vacuolar organelles. Other groups have 
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shown that VEGF upregulates intercellular adhesion molecule-1 which facilitates 
permeability and leukocyte stasis in the retina (Miyamoto et al. 2000). VEGF 
stimulation has also been shown to cause phosphorylation of tight junction 
proteins occluding and zonula occludens-1 leading to increased barrier 
permeability (Antonetti et al. 1999).  
Neuropilins 
Neuropilins (NRP) are single-pass, non-tyrosine kinase surface receptors that 
have been implicated in many physiological processes and pathological conditions 
(Staton et al. 2007).  Neuropilins are 130-kDa transmembrane glycoprotein receptors that 
function in both neuronal guidance and angiogenesis. Neuropilins 1 and 2 are encoded on 
different chromosomes (10p12 for NRP1 and 2q34 for NRP2) but both are comprised of 
17 exons (Rossignol, Gagnon, and Klagsbrun 2000). NRP1 and NRP2 have domain 
structure similarity: both have an N-terminal extracellular domain, a transmembrane 
region, and a cytosolic tail region. The extracellular domain contains two CUB 
(complement binding factors C1r/C1s, Uegf, bone morphogenetic protein 1) domains 
(a1/a2), two factor V/VIII coagulation factor homology domains (b1/b2), and a MAM 
(meprin/A5-protein/PTPmu) domain joined by a b-c linker domain (Soker et al. 1998).  
Neuropilin 1 and 2 share 45% structural homology but differ vastly in their cytosolic 
domains. The CUB and b1 domain is required for the binding of semaphorin ligands 
while the b1/b2 domains are VEGF binding domains. The b1/b2 domains, usually found 
in coagulation factors and discoidin proteins, are recognized for their role in cell-cell 
adhesion due to its ability to bind cell surface anionic phospholipids. More importantly, 
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this is also the site of competition between semaphorins and VEGF binding. In addition, 
the MAM domain is key for receptor homo- or hetero-dimerization (Klagsbrun, 
Takashima, and Mamluk 2002). 
 
Figure 3 | Organization and structure of neuropilin receptor. The general domain 
structure of neuropilins is comprised of extracellular CUB, F V/VIII, and MAM domains, 
a transmembrane domain, and a cytosolic tail. Both neuropilin-1 and neuropilin-2 can 
have soluble and transmembrane forms. Neuropilins also have SEMA binding and VEGF 
binding domains that overlap. The MAM domain is hypothesized to aid in 
oligomerisation. Some forms of neuropilin have a PDZ binding motif (SEA) in the 
cytoplasmic tail which can bind cytoskeletal elements such as synectin. Taken from Roy 
et al. (2017).  
 
Neuropilin variants and isoforms  
 There exists many splice variants reported for both NRP. Nrp can be alternatively 
spliced to either a soluble form or membrane-bound form. There exists four known 
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soluble forms of NRP1: s11NRP1, s12NRP1, sIIINRP1, and sIVNRP1. s11NRP1 and 
s12NRP1 arise from pre-mRNA processing of introns 11 and 12.  S9NRP2 is the soluble 
form of NRP2. The soluble isoforms have many common features. These truncated forms 
of NRP contain the a and b domains but lack the c, transmembrane, and cytoplasmic 
domains. As a result, these soluble forms contain both semaphorin and VEGF binding 
domains, a1/a2/b1 and b1/b2 respectively. In addition, they contain a unique amino acid 
sequence at the 3’ ends derived from the 5’ end of their associated intron not found in 
full-length neuropilin. It’s hypothesized that these soluble isoforms, similar to soluble 
VEGFR-1, serve as a sink for NRP associated ligands such as VEGF-A (Hornig et al. 
2000; Gagnon et al. 2000). NRP2 exists as two major isoforms, NRP2a and NRP2b, 
which share 100% homology except in the transmembrane and cytosolic regions. The 
significance of this difference lies in the lack of a distinct cytoplasmic PDZ domain 
recognition sequence SEA shown to be required for synectin binding in NRP1. In NRP1, 
it is reported that this PDZ-binding domain helps facilitate NRP1-VEGFR-2 complex 
formation (Prahst et al. 2008). Moreover, synectin has been implicated in cell migration, 
receptor internalization, and arterial vessel development (Gao et al. 2000; Hermans et al. 
2010; Naccache, Hasson, and Horowitz 2006). Recently, it has been shown that NRP2b 
isoform selective expression by non-small cell lung cancer cells correlates with increased 
cell migration and metastasis (Gemmill et al. 2017). 
NRP interactions with VEGF receptors 
 In endothelial cells, NRPs serve as co-receptors for VEGFRs by complexing and 
forming a functional unit. For instance, NRP1 co-expression with VEGFR-2 on 
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endothelial cells enhances VEGF-induced chemotaxis, VEGF binding to VEGFR-2, 
VEGFR-2 phosphorylation, and associated downstream VEGF-induced signaling (Soker 
et al. 1998). This enhanced signaling effect is due to an increase in VEGF-VEGFR 
complex formation (Pan et al. 2007; Soker et al. 2002) aided by NRP1-mediated VEGFR 
receptor clustering and not due to effects on binding affinity (Whitaker, Limberg, and 
Rosenbaum 2001). While it has been shown that NRP-VEGFR complex formation can 
greatly enhance VEGFR signaling, it is by no means required (Jia et al. 2006; Soker et al. 
2002). Another possibility is that NRP-VEGFR complex formation stabilizes VEGFR 
and renders it less prone to receptor-mediated endocytosis (Holmes and Zachary 2008). 
Class 3 Semaphorins 
Semaphorins are secreted and transmembrane proteins that were originally 
discovered as axonal guidance proteins critical in nervous system development. Class 3 
semaphorins (SEMA3s) are secreted proteins that were first discovered as neuropilin 
receptor ligands in axonal guidance (Kolodkin et al. 1997) but now have been implicated 
in anti-angiogenesis, immune system defenses, and inhibition of tumor progression 
(Kumanogoh and Kikutani 2003; Nasarre, Gemmill, and Drabkin 2014). SEMA3s are 
one of five vertebrate families of semaphorins. The class consists of seven soluble 
proteins (SEMA3A-G) that are ~100kDa in size and secreted by many cell types. 
SEMA3s can bind to neuropilins via an N-terminal 500 amino acid conserved Sema 
domain. After binding to a NRP receptor, the complex then couples with another family 
of proteins, Plexins, to form a functional signaling unit.  
SEMA3s and VEGF binding competition  
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One of the proposed ways that SEMA3s can regulate angiogenesis and vascular 
functions is through competition for VEGF-binding for the neuropilin receptor. Many 
biologically active peptides such as growth factors and hormones are released as inactive 
immature forms and require post-proteolytic processing for bioactivity (Adams et al. 
1997). It has been shown that SEMA3s possess a RXRR furin recognition site in its C-
terminal domain that can be proteolytically cleaved from to pro-protein form into an 
active form. Semaphorin and VEGF share an overlapping binding site in the b1 domain 
of neuropilin (Nasarre, Gemmill, and Drabkin 2014). This process form of SEMA3 
impedes on the ability of VEGF binding to neuropilin (Parker et al. 2010). However, 
unprocessed forms of SEMA have also biological relevance. For example, cleaved 
SEMA3E has been shown to promote cancer cell metastasis via PlexinD1. The 
unprocessed form has been shown to compete with the processed form in tumor cells, 
serving as an potent anti-angiogenic factor (Casazza et al. 2012). 
Plexin receptors 
Not much known about Plexin receptors except that they are transmembrane 
glycoprotein receptors with a cytoplasmic domain exhibiting tyrosine kinase activity. 
Plexins also seem to be able to interact with many other receptors other than NRPs, such 
as Scatter Factor receptors and integrins (Bork et al. 1999; Conrotto et al. 2004). While 
class 4, 5, and 6 semaphorins can bind to plexins and signal directly, class 3 semaphorins, 
with the exception of SEMA3E (Gu et al. 2005), needs the plexin-neuropilin complex to 
bind and signal successfully. It is understood that SEMAs bind to plexins for signal 
transduction; however the specific pathways of Plexin signal transduction remains a 
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relative mystery. For instance, while SEMA3’s ability to bind to neuropilins to induce 
cytoskeletal collapse via plexins is clear, the associated Plexin signaling pathway not 
been thoroughly elucidated (Gelfand, Hong, and Gu 2009). Moreover, certain specific 
combinations of NRP and plexins can determine the specificity of the ligand and the 
downstream signaling pathways. For example, Plexin 1 does not bind SEMA3A alone, 
but the NRP1-plexin 1 complex has a higher affinity for SEMA3A binding than NRP1 
alone (Takahashi et al. 1999).  
 
Figure 4 | SEMA3s, NRPs, and plexins exhibit specific interactions. Diagram of the 
different ligand-receptor binding affinities for SEMA3s, NRPS, and plexins. Adapted 
from Gaur et al. (2009). 
 
SEMA3F-NRP2 Axis in Acute Cutaneous Inflammation 
 Published research from our lab has shown that NRP2 deficient mice exhibit 
greater edema during delayed-type hypersensitivity reactions compared to wild-type 
littermates. Furthermore, significantly increased vascular permeability was observed in 
the NRP2 deficient mice compared to wild-type mice (Figure 5). Immunohistochemistry 
 22 
also showed a lack of superficial lymphatic vessels in NRP2 knockout mice due to 
developmental deficits in the lymphatic architecture (Mucka et al. 2016). Taken together, 
the observed increased edema in congenital NRP2 deficient mice is associated with both 
a loss in vascular permeability and an impairment of lymphatic drainage from the loss of 
properly developed lymphatic vessels. Our lab further showed that exogenous addition of 
SEMA3F recombinant protein can abrogate the effect of VEGF-induced vascular 
permeability (Figure 6).  
  
Figure 5 | Vascular Permeability associated with SEMA3F and NRP2. In Miles 
assays, recombinant SEMA3F (S3F) protein inhibits vascular endothelial growth factor 
(VEGF) induced vascular permeability when injected into the mouse skin (left). Vascular 
permeability of NRP2 knockout (KO) mice was greater than wild-type (WT) and 
heterozygous (HET) mice during DTH reactions (right) (Mucka et al. 2016). 
 
 Our lab has shown the presence of endogenous SEMA3F in the epithelium and 
hair follicles through immunohistochemistry and immunoblotting (Figure ) Uchida et al. 
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(2015) has also shown the presence of SEMA3F in the epidermis through in situ 
hybridization (Uchida et al. 2015).  
 
Figure 6 | SEMA3F expression is present in the skin. SEMA3F is shown to be present 
in the skin via immunoblot analysis of wild-type ear lysate (left). Paraffin sections of 
mouse skin were stained with SEMA3F antibody (brown) (Mucka et al. 2016). 
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OBJECTIVES 
The goal of our investigation was to determine the role of SEMA3F in acute 
inflammation. Previous studies of SEMA3F have focused on its anti-antiangiogenic 
properties as it relates to cancer tumorgenesis and metastasis (Bielenberg, Shimizu, and 
Klagsbrun 2008a; Bielenberg et al. 2004). During acute cutaneous inflammation 
SEMA3F’s physiological role in the skin has yet to be elucidated. In some pathologies 
such as psoriasis, there is epidermal inflammation correlated with an observable 
increased in VEGF overexpression and noticeable microvascular hyperpermeability 
(Simonetti et al. 2006). SEMA3F’s ability to compete with VEGF-A binding to NRP2, 
often yielding opposing VEGF effects (Nasarre et al. 2003), and ability to inhibit 
endothelial actin stress fiber formation (Bielenberg, Shimizu, and Klagsbrun 2008b) 
prompted us to investigate its role in vascular permeability and inflammation. Our lab has 
previously shown that SEMA3F can inhibit VEGF-A induced vascular permeability 
under normal physiological conditions. We have decided to proceed further and 
investigate SEMA3F’s role as a potential anti-inflammatory agent serving to limit 
excessive VEGF-induced permeability in acute cutaneous inflammation.  
Specifically, we plan to analyze SEMA3F’s role when both overexpressed and 
neutralized under the acute inflammatory setting. We hypothesize that SEMA3F 
overexpression will lead to a quicker resolution of inflammation. Conversely, SEMA3F 
neutralization will lead a more prolonged inflammatory event. Future experiments will 
focus on using SEMA3F knockout transgenic mice to evaluate the effect of complete 
SEMA3F knockout during inflammation.   
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METHODS 
 
 Cell Subculture, Thawing, and Cryopreservation 
Cell lines: The adherent cell lines used are human glioblastoma cells (U-87 MG), 
human embryonic kidney cells (HEK293A), immortalized keratinocyte from adult human 
skin (HaCaT) cells,  and hTERT immortalized human bladder urothelial cells (TRT-
HU1). U-87 MG were purchased from the American Type Culture Collection (ATCC). 
HaCaT cells were kindly provided by Dr. Michael Detmar (Switzerland). HEK293A and 
TRT-HU1 cells were obtained from Dr. Rosalyn Adams (Department of Urology, Boston 
Children’s Hospital). Immortalized HEK293A cells are more strongly adherent and 
transfectable than the widely used HEK293T and hence more conducible for adenovirus 
production. Most of the cell lines were cultured in complete media: Dulbecco’s Modified 
Eagle Media (DMEM) with high glucose concentration supplemented with 10% Fetal 
Bovine Serum (FBS), 1% Penicillin-Streptomycin-Glutamine (GPS), and 1% MEM Non-
Essential Amino Acid (NEAA) (Gibco). TRT-HU1 cells are urothelial cells immortalized 
with human telomerase reverse transcriptase that were used to ascertain the multiplicity 
of infection of the adenovirus. They were cultured in high glucose DMEM, 10% FBS, 
1% GPS, 1% NEAA, and 0.1% thioglycerol. All cell lines are cultured in 10 centimeter 
(cm) tissue culture (TC)-treated dishes (Corning Falcon). Cells are cultured at 37°C in a 
humidified chamber with 5% CO2 in air.  
Subculturing: Tryspin/Ethylenediaminetetraacetic acid (EDTA), DMEM, and 
Phosphate Buffered Saline (PBS) are all prewarmed for at least 20 minutes in a 37°C 
warm water bath. Cells are grown and assessed every day to determine health and 
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confluency. Upon reaching 70-80% confluency, media is removed and cells are washed 
once with 5 milliliter (mL) of PBS. 0.5 mL of 0.05% Trypsin/EDTA is pipetted onto the 
cell monolayer and incubated at 37°C and 5% CO2 in air for 2-5 minutes until all cells are 
in suspension. 9 mL of fresh pre-warmed media is pipetted into the dish to neutralize 
trypsin enzymatic activity. After, 1 mL of the resuspended cells/media is transferred into 
a new 10 cm dish with 9 mL of prewarmed media and placed back into a 37°C and 5% 
CO2 incubator. 
Thawing: Cells are removed from liquid nitrogen storage and slowly thawed in a 
37°C warm water bath. Upon complete thawing, media with cells was pipetted from the 
cryogenic vial into a 10 cm dish with 15 mL of prewarmed complete media and placed 
inside a 37°C and 5% CO2 incubator. The next day, media was changed to remove any 
trace amounts of DMSO. 
Cryopreservation: Cells at 70-80% confluency were detached from a 10 cm dish 
using 0.025% trypsin/EDTA, resuspended in media, then centrifuged at 1000 revolutions 
per minute (rpm). After, the media was removed and the pellet was resuspended in 5 mL 
of freezing media (70% complete media, 20% FBS, 10% dimethyl sulfoxide (DMSO)). 
The solution was then aliquoted by 1 mL into cryogenic vials. The vials are stored 
overnight at -80°C in a Mr. Frosty freezing container (Thermo Fisher Nalgene). After at 
least 8 hours, the cryogenic vials were transferred to liquid nitrogen for long-term 
storage. 
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Neuropilin 2 Transgenic Mice 
All mice were housed in a high barrier level animal facility at Boston Children’s 
Hospital and were maintained by Animal Resources at Children’s Hospital (ARCH). 
Neuropilin-2-knockout reporter mice (JAX stock #006700) were purchased from Jackson 
Laboratories. These mice possesses a Nrp2 targeted mutation in which exon 1 and the 
first part of intron 1 are excised and a green fluorescent protein (GFP) sequence is 
knocked in (Walz, Rodriguez, and Mombaerts 2002). Nrp2 heterozygous mice (Nrp2+/-) 
are used to breed and maintain the colony, generating both wild-type (Nrp2+/+) and 
knockout (Nrp2-/-) mice in F1 offspring. Nrp2 mice were genotyped by cutting a piece of 
ear tissue and microscopically visualizing the hair follicles under ultraviolet light. Nrp2 is 
highly expressed in the hair follicle in adult mice, therefore the hair follicles of NRP+/+ 
will not fluoresce while Nrp2-/- mice will. However, Nrp2+/- mice fluoresce similarly to 
the Nrp2-/- mice so pieces of tissue from GFP fluorescent Nrp2 mice were sent to 
Transnetyx for further genotyping. All mice used for experiments were conducted on 
female C57BL/6 mice generated from Nrp2 heterozygous breedings.  
Protein Assay 
Protein concentrations of cell or tissue lysates were determined using an improved 
Lowry colormetric assay following the manufacturer’s microplate assay protocol (Bio-
rad DC Protein Assay). A Bovine Serum Albumin (BSA) dilution standard was prepared 
using the same buffer as the sample. The 96-well microplate was read by a VERSAmax 
microplate reader (Molecular Devices) at 650 nm wavelength. Protein concentrations 
were calculated from the BSA standard curve.  
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Semaphorin 3F Adenovirus Purification 
In order to understand the physiological implications of systemic SEMA3F 
overexpression, a human recombinant type 5 adenovirus (Ad) was utilized as a delivery 
vehicle. Adenoviruses have a protein capsid that encompasses a linear duplex DNA 
genome. DNA viruses such as adenoviruses infect quiescent cells and through viral 
regulatory proteins, forces the cell into the DNA replication phase (S phase) to synthesize 
viral DNA. Starting at day 1 post-infection virions assemble in the nucleus and after a 
span of a few days, the cell lyses and releases these infectious virions (Wold and Toth 
2013). Our Ad vectors are modified versions of Ad5 that are replication-defective (RD). 
These RD vectors have the E1A and E1B genes deleted and replaced with a high activity 
promoter which drives expression of the gene of interest. These E1 gene deletions 
prevent Ad replication in living cells but also inhibits the host cell’s apoptotic response to 
Ad infection (Wold and Toth 2013). After intravenous administration, Ad vectors reach 
the liver via the portal vein within minutes and then become sequestered. The 
fenestrations of the hepatic sinusoidal walls allow Ad particles to pass and efficiently 
reach the hepatocytes, which then is uptaken by both hepatocytes and Kupffer cells 
(Alemany, Suzuki, and Curiel 2000; Shayakhmetov et al. 2004). Adenoviruses are 
transient transductions, which can reach high transduction efficiencies due to the higher 
achievable viral titers, but then gene expression is lost over weeks to months due to 
replication deficiency (“Cell Culture - Adenovirus Techniques | ABM Inc.” n.d.). 
Moreover, Ad vectors are immunogenic and intravenous injection into mice produces an 
almost instantaneous innate immune response directed against the capsid proteins. 
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Dosages should be calculated with care because at a threshold dose of viral particles 
(1010), a lethal response is generated (Muruve 2004). 
Propagation: On day 1, HEK293A cells were seeded into two 10 cm dishes at a 
cell density of 1.5 x 106 cells per 10 mL DMEM media, and two 15 cm dishes with twice 
the density of the 10 cm dishes and 15 mL of media. Cells were allowed to propagate.  
On day 3, one of the 10 cm dishes was infected with a low titer viral supernatant 
originally provided by Dr. Rosalyn Adam. Also on day 5, one 15 cm dish was plated with 
1.5 x 106 cells (15 ml of media per dish) and another twelve 15 cm culture dishes are then 
seeded with 3.0 x 106 cells (15ml of media per dish). The cells were allowed to grow and 
on day 6, the conditioned media with attached cells from the 10 cm dish infected on day 3 
was collected. Repeated aspiration of the media using a serological pipette was used to 
detach the HEK293A cells. In order to release the viral content from inside the cells, the 
harvested conditioned media was transferred to a 50 mL polypropylene conical tube 
(Corning Falcon) and placed in a -80°C freezer. After the conditioned media was 
completely frozen, the tube was then placed in a 37°C water bath to completely thaw. 
This process was repeated two more times. Afterwards, the conditioned media with the 
cell debris was centrifuged at 2500 rpm for 15 minutes. The adenovirus containing 
supernatant was then collected for further viral infections. On the same day, 1 mL of the 
supernatant was added to 14 mL of DMEM media and was used to change the media of 
the 15 cm dish plated on dish day 3. The rest of the supernatant was aliquoted and stored 
at -80°C. On day 8, the conditioned media with cells of previous infected 15 cm dish was 
collected, freeze-thawed a total of three times, and supernatant harvested as per the 
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previous described protocol. 1 mL of the supernatant was used to infect each of the 
twelve 15 cm HEK293A seeded dishes plated on day 5. On day 10, the conditioned 
media from the twelve 15 cm dishes were harvested and pelleted at 1500 rpm for 5 
minutes. After, 10 mL of fresh media is added and using a 10 mL serological pipette, the 
pellet is resuspended. The solution is freeze-thawed three times and after the third thaw, 
the cell lysate is transferred into a new 50mL centrifuge tube. The tubes are centrifuged at 
2500 rpm for 20 minutes. The supernatant is collected into a clean 50 mL polyprolene 
centrifuge tube and the pellet is discarded. If the supernatant had observable debris, the 
tube cell lysate was centrifuged again.   
Clarification: The purification of adenovirus was performed using the Fast- Trap 
adenovirus Purification and Concentration Kit (EMD Millipore). Benzonase nuclease was 
added (1µL per 10mL of crude adenovirus) to the crude virus collected in the previous 
step. The container was inverted to mix thoroughly and incubated at 37°C for 30 minutes. 
In a biosafety hood, the Steriflip-HV filter tube was connected to the virus sample tube. 
The unit was then flipped so that the conditioned media could be vacuum filtered through 
into the Steriflip-HV tube. The vacuum was then connected and the crude adenovirus 
filtered. The virus was then eluted and collected into an empty 50 mL tube using the 
provided Wash and Elution buffers in the kit. The adenovirus was then further 
concentrated and buffer exchanged from DMEM/PBS to PBS using an Amicon Ultra-4 
filter unit (50,000 NMWL). The virus was aliquoted and stored in -80°C.  
Virus staining: The virus titer of each new batch was determined by viral staining. 
HEK293A cells were plated at 2.5 x 105 cells/mL into each well of a 24-well plate. Serial 
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dilutions of virus were diluted in PBS to 10-4, 10-5, 10-6, and 10-7 of the original viral 
concentration and 50µL of each dilution was used to infect each well 24 hours after cell 
plating. After 48 hours of incubation at 37°C with 5% CO2, the HEK293A cells are then 
fixed using ice cold methanol for 20 minutes. Using the Adeno-X Rapid Titer Kit 
(Clontech), the fixed cells were stained with a mouse anti-hexon antibody for 1 hour at 
37°C. The cells were washed three times with PBS for 3 minutes each. Using a 1:200 
PBS-diluted biotinylated anti-mouse antibody (Cell Signaling Technology), the antibody 
was incubated for 1 hour at room temperature on an orbital shaker. Next, we added a 
horseradish peroxidase (HRP) labeled avidin to enhance the signal. We then stained with 
3,3'-diaminobenzidine (DAB) substrate so that hexon expressing cells turn brown. 
Positive cells are counted in three different fields under 200x magnification and the 
infections units (IFU) is calculated from the resulting average number of positive 
cells/unit dilution. The formula for calculating IFU/mL for each well is as follows: 
(infected cells/field) x (fields/well)
volume virus (ml) x (dilution factor)
 
Multiplicity of Infection: The multiplicity of infection (MOI) was conducted to 
determine the functionality of the purified virus. The MOI can help determine the dose 
and time responses parameters of SEMA3F production after viral infection. TRT-HU1 
cells were plated at a density of 8,000 cells and 2 mL of DMEM per well in a 12-well 
plate. After a 24-hour incubation period at 37°C, TRT-HU1 cells were infected with the 
adenovirus (Day 0) at 8 x 103 (1X), 8 x 104 (10X), and 8 x 105 IFU (100X). 1 mL of the 
conditioned media from each well was collected at Days 0, 1, 2, and 3 following viral 
infection. Also, other wells were infected with 8 x 105 (100X) cells and 1 mL of media 
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was collected at 24, 48, 72, 96 hours. After collection of the media, 6 µL of 6X sodium 
dodecyl sulfate (SDS) reducing buffer was added per sample and boiled at 95°C for 10 
minutes before they were analyzed using polyacrylamide gel electrophoresis (PAGE).  
Tissue Cryopreservation and Protein Extraction 
Target tissues were extracted and placed in microcentrifuge tubes, snap frozen in 
liquid nitrogen and then stored in -80°C until ready for protein extraction. To extract, 
frozen organs were pulverized using a BioPulverizer (Bio Spec Products), collected into a 
tissue grinder (Kimble Kontes) with Radio-Immunoprecipitation Assay (RIPA) lysis 
buffer (500 µL per 50 mg of tissue; Boston Bioproducts) with protease inhibitor (Roche). 
After grinding, protein lysates were collected in a microcentrifuge tube and incubated on 
ice for two hours with periodic vortexing. Samples are then centrifuged at 14,000 rpm at 
4°C for 15 minutes. The supernatant was stored in -20°C. 
Western Blot Analysis 
All samples were equally loaded based on total protein concentration values. 
Samples and ladders are prepared using 6X reducing SDS sample buffer (Boston 
Bioproducts). Samples were then boiled at 95°C for 10 minutes. 7.5% SDS-PAGE gels 
were placed in a gel electrophoresis apparatus (Bio-Rad) with running buffer (Boston 
Bioproducts). Wells were flushed to remove unpolymerized gel before sample loading. 
Roughly 40 µL of sample was loaded per well in 1.5 millimeter (mm) thick wells. 
Samples and ladder were then loaded and set to migrate for roughly 2 hours at 100V. 
Once resolved, proteins were transferred to a nitrocellulose membrane (Bio-Rad) for 2 
hours at 300mA in transfer buffer (Boston Bioproducts). The membrane was then stained 
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with Ponceau S to verify complete protein transfer. Next, the membrane was incubated 
with 5% non-fat milk in TBST (50mM Tris, 150mM NaCl, 0.1% Tween 20) for an hour 
at room temperature. The membrane was then incubated on a rocker in primary antibody 
diluted 1:1000 in TBST overnight at 4°C. The membrane was then washed 3 times in 
TBST for 15 minutes. After, the membrane was incubated in HRP-labeled secondary 
antibody on a shaker for 1 hour at room temperature. Then the membrane was washed 
again 3 times in TBST for 15 minutes. The membrane was then incubated with a lumino-
based substrate for HRP-catalyzed detection (Perkin Elmer) following the manufacturer 
guidelines and visualized using a ChemiDoc imaging system (Bio-Rad). 
Detecting SEMA3F in Keratinocytes 
HaCaT cells were seeded at 20% confluency and grown in a 10 cm dish with 
complete media. 1 mL of conditioned media was collected at 24, 48, and 72 hours after 
seeding and stored in -20°C. After 72 hours, a western blot was performed to detect 
SEMA3F expression levels. 
SEMA3F Recombinant Protein Purification 
C-terminally histidine(His)-tagged SEMA3F was previously purified by other lab 
members (Bielenberg, Shimizu, and Klagsbrun 2008b). Briefly, HEK293 cells are grown 
and then transiently transfected with pSecTag2A SEMA3F plasmid. After 16 hours, the 
growth media is changed to serum-free CD293 medium (Invitrogen, 20ml/dish). After 48 
hours, conditioned media was collected and purified by FPLC through a nickel affinity 
column. The C-terminal histidine tag will bind with high affinity to nickel. A HiTrap 
high-performance chelating column (GE Healthcare Amersham Biosciences) is prepared 
 34 
with NiSO4 and connected onto a FPLC machine. The conditioned media is loaded into 
the FPLC machine and then washed with wash buffer. The SEMA3F protein is then 
eluted with an imidazole elution buffer and collected into low-adhesive tubes (PGC 
Sciences). A PD-10 column was used to remove the salt and imidazole from the protein. 
The purified SEMA3F protein is then aliquoted and stored at -80°C.  
Delayed-type Hypersensitivity (DTH) Mouse Ear Model 
 Sensitization: A 2% solution of oxazolone (4-ethoxymethylene-2 phenyl-2-
oxazoline-5-one; SigmaAldrich) was made by dissolving oxazolone powder in a mixture 
of acetone/olive oil (4:1 vol/vol). The mouse is anesthetized using isoflurane. The 
abdomen of each mice was shaved and 50 µL of the 2% oxazolone solution was topically 
applied. Next, 5 µL of 2% oxazolone was applied to each paw of the mouse.  
 Challenge: Five days after sensitization, only one ear will be challenged (Day 0) 
by topical application of 20 µL (10 µL to each side) of 1% oxazolone dissolved in a 
mixture of acetone/olive oil (4:1 vol/vol). Ear thickness is then measured at days 0, 1, 3, 
5, 7 or daily after oxazolone challenge using a thickness gauge (Mitutoyo). Ears were 
measured twice and the average increase in ear thickness over baseline thickness (Day 0, 
before challenge) was graphed versus time. For the SEMA3F western analysis, whole ear 
tissue was cut from mice at the desired days and stored in -80°C.   
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Figure 7 |  Timeline of DTH mouse model. Mouse is shaved ventrally and 2% 
oxazolone is applied to its abdomen (Day -5). After 5 days, 1% oxazolone is topically 
applied to its ear (Day 0). Ear thickness is measured daily as a readout of inflammation 
until Day 9. 
 
Testing Neutralizing Ability of SEMA3F Antibody 
A polyclonal antibody was generated against the sema domain of SEMA3F and 
purified from rabbit serum. The antibody exhibits SEMA3F specificity and has been 
shown to not bind to other class 3 semaphorins through western blot analysis (Coma et al. 
2010). In a 6-well plate, U87-MG cells were plated at 50% confluency with 2 mL of 
Eagle’s Minimum Essential Medium (MEM) supplemented with 1% GPS per well. After 
24 hours, SEMA3F protein or SEMA3F protein with SEMA3F antibody was 
administered in a dose dependent manner. One hour prior to treatment, SEMA3F 
recombinant protein and SEMA3F antibody were co-incubated at room temperature in a 
0.2ml centrifuge tube. SEMA3F recombinant protein was also incubated at room 
temperature for the same amount of time. After 1 hour of treatment at 37°C with 5% 
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CO2, cells were lysed and protein was extracted according to protocol and then analyzed 
through western blot analysis. Serine 473 phosphorylated-Akt (#sc-7985-R, Santa Cruz) 
levels, Akt (#9272, Cell Signaling Technology), and beta actin protein levels (#sc-47778, 
Santa Cruz) were analyzed.  
 
DTH – SEMA3F Neutralizing Antibody Administration 
 DTH reactions were induced on one ear of eight to ten week old female mice 
according to protocol. Mice were anesthetized and were injected intraperitoneally with 
100 µL of SEMA3F neutralizing antibody (0.76mg/mL) or rabbit serum (60mg/mL; 
Jackson Immunoresearch Laboratories) on days 0, 2, and 4 after oxazolone challenge. Ear 
measurements were taken on days 0, 1, 2, 3, 4, 7.  
 
DTH – SEMA3F-adenovirus Administration 
 DTH reactions were induced on one ear of eight to ten week old C57/B6 female 
mice according to protocol. Mice were anesthetized and injected via tail vein (Day -3) 
with SEMA3F adenovirus or control adenovirus 3 days prior to DTH challenge. 
Adenovirus was taken from -80°C storage and injected immediately after complete 
thawing. Ear measurements were taken daily for seven days.  
Modified Miles Assay  
 Modified Miles assays were conducted in SEMA3F adenovirus injected wild type 
mice at Day 2 after DTH oxazolone challenge. This experiment was conducted on five 
female wild type mice between 8-12 weeks of age. Mice were sensitized withs 2% 
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oxazolone according to protocol (Day -5). At Day -3, SEMA3F-Ad or Control-Ad were 
intravenously injected into anesthetized mice. At Day 0, mice were challenged with 1% 
oxazolone per previous protocol on one ear. At Day 2, mice were anesthetized and Evans 
Blue dye (100 µL of a 1% solution in PBS) was injected via tail vein. After 1 hour, the 
mice were euthanized in a CO2 chamber and a tissue section of the ear was taken. The 
area and thickness of the ear piece was recorded. The tissue was then incubated in 400 µL 
of formamide at room temperature for 5 days to allow the dye to extravasate from the 
tissue into solution. The absorbance was measured by a VERSAmax microplate reader 
(Molecular Devices) at 570 nm. The optical density of the extracted dye was normalized 
to surface area (cm) of tissue calculated using ImageJ software.  
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RESULTS 
Unsuccessful Detection of SEMA3F Secretion in Human Keratinocytes  
 Given the wide area of epidermal SEMA3F expression shown by Uchida et al. 
(2015) and Mucka et al. (2016), we believed keratinocytes to be the major producer of 
SEMA3F in the epidermis as opposed to melanocytes or other antigen presenting cells 
(APCs) (Brown et al., 1992). HaCaT cells are widely used in studying skin biology, 
keratinocyte differentiation, and epidermal pathophysiology due to their high capacity to 
grow and differentiate (Seo et al. 2012; Wilson 2014; Shahrabi-Farahani et al. 2014). 
However, SEMA3F detection in the conditioned media via Western blot analysis was 
unsuccessful (data not shown) although positive control SEMA3F protein lane was 
detected. Future experiments will look at HaCaT SEMA3F mRNA expression. In 
addition, further immunoblot analysis should be conducted after the appropriate 
conditioned media purification. Secreted proteins are normally secreted at low 
concentrations in culture media. Therefore, methods of protein concentration such as 
using immunoprecipitation with SEMA3F antibody or glycoprotein purification using 
Concanavalin A should be considered. 
SEMA3F is Upregulated in Delayed-type Hypersensitivity Reactions 
We have previously shown that SEMA3F is endogenously expressed in the skin 
epithelium under normal physiological conditions (Figure 6) (Mucka et al. 2016). 
Western blot analysis of whole ear tissue lysate confirms that SEMA3F protein is 
upregulated during DTH reactions. The amount of SEMA3F protein synthesized is 
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increased significantly over basal levels. Unfortunately, Day 3 tissue lysate was not 
collected due to technical error.  
 
Figure 8 |  SEMA3F expression increases during DTH inflammation. Protein from 
whole ear mouse lysates were taken on Days 0, 1, 5, 7 after DTH challenge and analyzed 
for SEMA3F protein expression using a homemade SEMA3F antibody. Recombinant 
SEMA3F protein (1ug) was loaded as a control. 
 
SEMA3F Antibody Successfully Neutralizes Bioactive SEMA3F  
 To test the ability of the antibody to neutralize bioactive SEMA3F, the PTEN-
PI3K-AKT-mTOR pathway was analyzed since SEMA3F has been shown to regulate 
mechanistic targeting of rapamycin (mTOR) signaling (Nakayama et al. 2015). 
Specifically, SEMA3F has been shown to inhibit Protein kinase B (Akt) activity through 
decreased phosphorylation in a time and dose dependent manner (Nakayama et al. 2015). 
U87-MG glioblastoma cells are known to have high NRP2 expression (Shimizu et al. 
2008) and a PTEN mutation leading to constitutive high levels of phosphorylated Akt 
(Pore et al. 2003). Upon SEMA3F administration, it has been shown that phosphorylated-
Akt levels decrease in U87-MG cells (Nakayama et al. 2015).  
Western blot analysis of U87-MG cells treated with increasing concentrations of 
SEMA3F recombinant protein showed decreased activation of Akt via serine 473 
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phosphorylation (Figure 9). Addition of SEMA3F antibody at 5X concentration of 
SEMA3F dosage attenuated this activation. Treatment of SEMA3F protein was shown to 
be bioactive and decrease phosphorylated Akt levels in U87-MG cells. Additionally, 
SEMA3F protein and antibody were shown to be bioactive even after 1 hour incubation 
at room temperature. Future studies may be necessary to test the bioactivity of lower 
concentrations of anti-SEMA3F. 
 
Figure 9 | SEMA3F antibody is able to neutralize bioactive SEMA3F recombinant 
protein. SEMA3F protein and SEMA3F antibody were added to the medium of U87-MG 
cells for 1 hour at 5% CO2. SEMA3F antibody and SEMA3F protein was co-incubated 
for 1 hour at room temperature prior to treatment. Western blot analysis of 
phosphorylated p-Akt (Serine 473), Akt, and beta-actin were conducted. SEMA3F 
protein at concentrations of 320ng/mL and 640ng/mL were shown to be bioactive 
through downregulation of p-Akt. In addition, SEMA3F antibody at five-fold times the 
concentration of SEMA3F protein served to abrogate the effects of SEMA3F protein. 
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SEMA3F Depletion during DTH Leads to Increased Edema 
 SEMA3F is known to antagonize VEGF binding to NRP2 therefore we 
hypothesized that SEMA3F depletion during DTH would lead a prolonged inflammatory 
response. SEMA3F antibody injected mice exhibited significantly increased ear thickness 
(p=0.02) at Day 2 compared to rabbit serum injected control mice (Figure 10). 
Significance was calculated using an unpaired student’s t-test. Error bars are calculated as 
± SEM. Ear thickness of both groups of mice eventually returned to similar levels, 
however still above baseline (Day 0) levels. We have observed in the past that full 
resolution might not happen until many weeks after challenge. Ear thickness 
measurements for Day 1 is highly difficult to measure given the amount of fluid present 
in the tissue. The thickness gauge measures at a force of less than 2 Newtons (N) 
however, measurements still generate enough force to compress the tissue and affect 
measurement precision. Day 2’s and onward measurements are more precise because the 
tissue is less compressible. Unfortunately, there is no commercial available SEMA3F 
neutralizing antibody; therefore, our supply of antibody limited the number of treatments 
to only three administrations. For future repetitions of this experiment, higher number 
experimental mice could possibly reduce the high error associated with low sample sizes. 
Furthermore, the ear thickness on Day 1 was on average lower than previous DTH 
experiments. This is most likely due to differences in amount of oxazolone applied during 
sensitization/challenging which could determine the degree of the inflammatory response.  
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Figure 10 | SEMA3F antibody treated mice exhibit more edema during DTH. 
C57/B6 wild-type mice were injected intraperitoneal with SEMA3F antibody on Days 0, 
2, and 4 after oxazolone challenge. Rabbit IgG was injected as a control. Significance 
was calculated using an unpaired student’s t-test. * = p < 0.05.  Data is represented as 
means ± SEM. 
 
SEMA3F Has No Significant Effect on Vascular Permeability in Modified Miles 
assay 
 Using a modified Miles assay, we observed that the average leakage of dye out of 
blood vessels in the Ad-SEMA3F treated group was half of the control group. However,  
low sample sizes and high variability of the data meant that the data did not reach 
significance (Figure 14). Significance was calculated using an unpaired student’s t-test. 
Error bars are expressed as ± SEM. Given the low sample sizes for the two sample 
groups, this experiment will be repeated in the near future.  
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Figure 11 | Vascular permeability under SEMA3F overexpression in DTH. Mice 
were injected via tail vein injection with His-SEMA3F adenovirus (Ad-SEMA3F) or 
control adenovirus (Ad-Ctrl) 3 days prior to oxazolone challenge. At Day 0, mice were 
challenged with 1% oxazolone on one ear. At Day 2, mice were anesthetized and Evans 
Blue dye (100 µL of a 1% solution in PBS) was injected via tail vein and tissues were 
taken after one hour and incubated in formamide (400 µL) for five days. Afterwards, the 
absorbance was measured at 570 nm. The optical density measured of each mouse was 
normalized to surface area (cm) of the collected tissue. Significance was calculated using 
an unpaired student’s t-test. Data is represented as means ± SEM. 
 
Bioactive SEMA3F Adenovirus was Successfully Purified 
Adenovirus viral titer: Using a hexon-specific antibody kit, infected cells were stained, 
and the viral titer was determined i.e. the lowest concentration of virus that is able to 
infect cells. Hexon protein is encoded by the adenoviral genome and is an essential 
component for adenoviral replication. Our purified adenovirus lacks the E1 gene product 
necessary for replication, however, utilizing HEK293A E-1 trans-complementing cells, 
only infected HEK293A cells will produce hexon proteins. Each stained cell corresponds 
to a single infectious unit (Figure 11). The number of cells in a field (200x magnification) 
were counted and used to calculate viral titer. The 10-4 dilution of the virus produced the 
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most clear and countable cells. The viral titer calculated for the adenovirus was 5.53 x 
109 IFU.  
 
Figure 12 | SEMA3F-Adenovirus has viral infection capability. Brown colored cells 
represents positively stained cells producing viral hexons. This is a representative view 
under a 200x magnification field. The 10-5 dilution of virus has more infected HEK293A 
cells than the 10-6 dilution determined by the difference in positively stained cell count. 
Images provided by Xiaoran Li. 
 
Adenovirus multiplicity of infection (MOI)  
In order to determine the dose and time parameters of the adenovirus infection, an 
MOI was conducted. Before injection of the adenovirus in vivo, we must ascertain how 
many viral particles the dose of viral injection and the timeframe in which SEMA3F 
secretion starts from the infected cells. MOI is the average number of virus particles 
infecting each cell or the ratio of infections units to the infection agents. Conditioned 
media was collected from TRT-HU1 cells infected cells 0, 24, 48, 72, 96 hours after 
infection and at different doses. The western blot analysis with an anti-histidine and anti-
SEMA3F antibody confirms the bioactivity of the SEMA3F adenovirus to infect 
epithelial cells in a dose and time dependent manner (Figure 12).  
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Figure 13 | SEMA3F Adenovirus infection exhibits time and dose dependent 
response. Conditioned media 24 hours post-infection was collected from TRT-HU1 cells 
(bottom). The 1X dose corresponds with 8 x 104 IFU.  Similarly, 100X dose of virus was 
used to infect TRT-HU1 cells and conditioned media was collected each 24 hours over 
the course of 72 hours (top). Immunoblot analysis was conducted with an anti-histidine 
antibody and SEMA3F antibody. Recombinant SEMA3F protein (45ng) was loaded a 
control. Data provided by Xiaoran Li.  
 
Successful Infection of SEMA3F Adenovirus In Vivo  
 To confirm in vivo the ability of His-SEMA3F-Ad to infect the liver and produce 
His-SEMA3F after intravenous injection, the virus was intravenously injected into five 
wildtype mice. Livers were extracted from these mice each day after adenovirus injection 
and analyzed using western blot analysis with an anti-histidine antibody (#25B6E11, 
Genscript). The liver lysates show a detectable amount of His-SEMA3F three days post-
injection. Detection lasts until 120 hours after injection. Expression of His-SEMA3F 
seems to start decreasing 96 hours after injections however we believe this to be due to 
technical errors (Figure 13). Transient infections of adenovirus are reported to last 21 
days. Further analysis is being conducted testing the lifespan of our SEMA3F transient 
infection. We expect the adenovirus infected cells to become transiently express 
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SEMA3F for a couple of weeks before host antigen-dependent immunity starts affecting 
expression (Kay et al. 1997). In collaboration with Dr. Adam’s lab (Urology Department, 
Boston Children’s Hospital), we have also shown that His-SEMA3F can also be 
detectable in the blood for many days after injection of SEMA3F-Ad (data not shown). 
 
Figure 14 | Adenovirus generated His-SEMA3F was detectable in the liver. This 
figure demonstrates the successful infection of the SEMA3F-Ad and ability to produce 
SEMA3F. Liver lysates were immunoblotted with an anti-histidine antibody. The top 
band corresponds with the active form of SEMA3F (~ 95kDa) and the bottom bands 
corresponds with the cleaved inactive form (~ 65kDa). SEMA3F recombinant protein 
was loaded as a control (300ng). Data provided by Benoit Niclou. 
 
SEMA3F Overexpression during DTH Reduces Edema   
SEMA3F or control adenovirus did not affect baseline levels of ear thickness in 
the two groups of mice. SEMA3F overexpression via adenoviral delivery during DTH 
inflammation resulted in a significant reduction in tissue swelling on Days 2 (p = 0.03), 3 
(p = 0.048), and 4 (p = 0.02) (Figure 14). Significance was calculated using an unpaired 
student’s t-test. Error bars are expressed as ± SEM. At Day 7, there was no significant 
difference in ear thickness between the two groups of mice. Also, the thickness of both 
groups did not return to baseline (Day 0). We did not take ear measurements of the two 
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groups of mice after Day 7. Average ear thickness in the control group seemed to 
increase at Day 4. One treated mouse was sacrificed during the experiment. We believe 
that anesthesia was administered at a higher than tolerable dose to that mouse during 
adenovirus injection which led to respiratory failure. For future repetitions of this 
experiment, higher number experimental mice could possibly reduce the high error 
associated with low sample sizes. 
  
 
Figure 15 | SEMA3F overexpression during DTH leads to decreased swelling. Five 
mice from each treatment group were injected via tail vein injection with His-SEMA3F 
adenovirus or control adenovirus 3 days prior to oxazolone challenge. Ears are measured 
daily from Day 0 to Day 7. A control adenovirus expressing no recombinant protein was 
used as a control. Significance was calculate using an unpaired student’s t-test. * = p < 
0.05.  Data is represented as means ± SEM.  
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DISCUSSION 
 
 Semaphorins and neuropilins have been studied extensively as regulators 
of neuronal and vascular guidance and angiogenesis. However, much less is known about 
the role of neuropilins and, more specifically, class 3 semaphorins in inflammation. In 
our study, we describe the role of SEMA3F in regulating the degree of edema formation 
during cutaneous inflammation. We conclude that while SEMA3F isn’t necessary for the 
development of an inflammatory response (presence of ear swelling), it seems modulate 
the length of inflammation by being upregulated in the early stages of a DTH response 
when vessels are hyperpermeable (Yi Luo and Dorf 2001), reinforcing our belief that 
SEMA3F impacts vascular permeability. The effect of SEMA3F depletion during this 
process leads to prolonged swelling while SEMA3F overexpression induces a quickened 
resolution to baseline levels. The implications of our findings will be discussed below. 
Keratinocyte as modulators of cutaneous inflammation 
 Keratinocytes are a key mediator of cutaneous inflammation. Keratinocytes are 
shown to be “signal transducers”, converting exogenous stimuli into the production of 
cytokines and other chemotactic factors involved in the initiation and amplification of an 
inflammatory response (Barker et al. 1991). During DTH, VEGF expression from 
epidermal keratinocytes is upregulated and its associated two receptors VEGFR-1 and 
VEGFR-2 are markedly increased on endothelial cells (Brown et al. 1992; Detmar et al. 
1994). This upregulation can be induced by the exogenous addition of an inflammatory 
cytokine such as transforming growth factor-alpha, suggesting an immune cell-mediated 
role in inducing keratinocyte VEGF expression during inflammation. Moreover, 
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abnormal keratinocyte VEGF overproduction has been linked to pathologies such as 
psoriasis (Brown et al. 1992; Detmar et al. 1994; Diaz et al. 2000). Production of 
SEMA3F most likely comes from keratinocytes (Mucka et al. 2016), which are a major 
source of cytokine and chemokine production in the skin (S. Y. Park et al. 2011). While 
we were unable to detect SEMA3F from HaCaT conditioned media, this is most likely 
due to technical error. However, the basal levels of secreted SEMA3F also might be low 
in HaCaT cells, so further concentration/purification steps or an addition of exogenous 
cytokines such as transforming growth factor-alpha to simulate an inflammatory setting 
might be required to reach a detectable threshold. Furthermore, the calcium concentration 
used in the culturing media can lead to varying keratinocyte expression profiles (Bikle et 
al. 1996). Therefore, calcium conditions used for culturing should be taken into 
consideration. High concentrations of calcium in the culturing media or FBS will induce 
a more terminally differentiated keratinocyte (corneocyte) phenotype while lower 
calcium concentrations will induce a more basal state (Bikle et al. 1996; Wilson 2014). In 
our study, we did not analyze the concentration of calcium in the culturing media. 
SEMA3F upregulation during inflammation 
SEMA3Fis expressed at basal levels in the skin, which suggests a possible role in 
maintaining tissue homeostasis. In the skin, SEMA3F is expressed in the epithelium 
while NRP2 is expressed on the endothelium (Mucka et al. 2016). We have shown that 
SEMA3F is upregulated in cutaneous tissue during DTH reactions (Figure 8). It has been 
shown that SEMA3F is only expressed in the epithelium of the skin under normal 
physiological conditions. However, future research should do protein expression/RNA 
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analysis on the different layers of the ear tissue e.g. epidermal, dermal, etc in 
inflammatory and non-inflammatory settings to confirm. This would account for the 
possibility that the observed increase in SEMA3F expression result from infiltrating 
leukocytes or from subsequent upregulation of SEMA3F in non-epithelium cells e.g. 
nerve cells, fibroblasts, etc. For instance, SEMA3F and NRP2 is expressed in T-cell acute 
lymphoblastic leukemia primary cells (Mendes-da-Cruz et al. 2014; Richeri et al. 2011). 
In addition, it has been shown that SEMA3’s can be secreted by macrophages and 
activated fibroblasts in inflamed tissue (Scheerer et al. 2017). Although we believe 
keratinocytes to be the major producer of SEMA3F in the skin, the production of 
SEMA3F from other cell types to aid in regulating permeability is another possibility 
worth further investigating.  
To aid us in determining SEMA3F’s role in the epithelium, our lab has now 
purchased tamoxifen-inducible keratin 14 (K14)-Cre transgenic mice (#004782; The 
Jackson Laboratory). These mice have a keratin 14 promoter that directly expresses the 
Cre recombinase enzyme. Using transgenic SEMA3F floxed mice (#005357; The 
Jackson Laboratory), deletion of the floxed sequences is possible in all K14-expressing 
cells in any ectoderm-derived tissue (skin, dental epithelium, etc.) upon tamoxifen 
treatment. Part of the current technical challenge is determining the optimal tamoxifen 
treatment schedule to generate higher levels of gene deletion. However, once known, 
experiments can be designed to study the contribution of SEMA3F in the skin on the 
regulation of edema formation after knockout. In addition, our lab has purchased 
SEMA3F constitutive knockout mice (#006710; The Jackson Laboratory), generated 
 51 
from deletions of exons 2-15 of the SEMA3F gene. The efficiency of SEMA3F gene 
deletion in the epithelium using the inducible K14 Cre-lox mice is under 100%, which 
prompted us to acquire the SEMA3F knockout mice (Walz et al. 2007). In addition, once 
a total knockout is obtained from SEMA3F+/- breedings, a DTH experiment will measure 
ear swelling between wild-type and SEMA3F knockout mice in order to recapitulate the 
results in the SEMA3F antibody experiment. Another benefit of obtaining these mice is 
using any observed developmental defects associated with SEMA3F loss of function to 
aid in determining SEMA3F’s pathophysiological role.  
SEMA3F’s role in regulating vascular permeability  
We have shown that SEMA3F can serve as a mediator of vascular endothelial 
permeability with potency similar to current anti-VEGF therapeutic drugs (Mucka et al. 
2016). Inflammation, characterized by increased vascular dilation, permeability, and 
leukocyte recruitment, is an essential mechanism in resolving injuries and maintaining 
homeostasis. Dysregulation of any steps of this pathway can lead to the development of 
pathologies. For example, incomplete clearance of the infilitrating leukocytes in 
susceptible individuals can result in chronic inflammation and fibrosis (Freire and Van 
Dyke 2013; Van Dyke 2007). Semaphorin 3F’s upregulation in the early stages (Day 1) 
of the inflammatory response coupled with the evidence of its effect on permeability 
(Figure 3) seems to suggest a possible role as an anti-permeability agent in the regulation 
of inflammation. In addition, SEMA3F expression during DTH reaches a maximum 
during Day 1 (although Day 2 and 4 were not checked), coinciding with maximal 
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increases in DTH microvessel permeability. Afterwards, SEMA3F expression decreases 
but persists above baseline levels (Day 0) throughout the resolution process. 
Increases in microvessel permeability have been observed in DTH reactions 
(Brown et al. 1995; Yi Luo and Dorf 2001). We have shown that endogenous SEMA3F 
depletion via delivery of SEMA3F neutralizing antibodies during DTH serves to prolong 
tissue swelling. We observed a significant difference only on Day 2. However, we 
hypothesized that Day 1 should exhibit the most significant difference since SEMA3F is 
maximally expressed at this time. Perhaps, SEMA3F expresson is maximal at Day 2 
which could explain this difference. In this experiment, the control rabbit serum was 
injected at 100X the concentration of the antibody. Possibly, the control group of mice 
generate a heightened immune response which facilitated T-cell or other immune cell 
effector functions, leading to a quickened resolution of inflammation (Obst 2015). Also, 
overexpression of SEMA3F through adenoviral delivery during DTH produced less 
edema. Similar to the previous experiment, the significant differences are at Days 2, 3, 
and 4 but not Day 1. Perhaps, there are saturated levels of SEMA3F in the 
microenvironment on Day 1. Research has shown that VEGFR-2 expression in the 
microenvironment increases during cutaneous inflammation (N. Zhang et al. 2004). 
Unfortunately, there is not much known about Plexin receptor activity during DTH 
reactions. We believe that overexpression of SEMA3F at Day 1 could therefore be 
insignificant in terms of affecting vascular permeability given the lack of available NRP2 
receptors or may be occupied by VEGF ligands. 
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Taken with our previous discovery that loss of the NRP2 receptor during DTH 
increases permeability suggests that SEMA3F seems to have a significant role in 
regulating vascular permeability. It has been shown that VEGF121 and VEGF165 and their 
receptors VEGFR-1 and VEGFR-2 and the co-receptor NRP1 are located both on the 
luminal and abluminal sides of the endothelium (Stefanini et al. 2009). Given this, 
SEMA3F might affect vascular permeability by changing the availability of NRP2 
receptors or increase localization of NRP2-Plexin clusters into functional receptor units 
which, upon SEMA3F binding, exhibits anti-permeability effects (Takahashi et al. 1999). 
Given the promiscuous nature of the NRP co-receptor, these downstream signaling events 
could be heavily dependent on receptor localization, expression, modification, 
oligomerization, or type.  
SEMA3F has also been observed at the junctions of interacting cells, suggesting a 
possible role in cell adhesion (Brambilla et al. 2000). Similar to another semaphorin, 
SEMA3A, it could activate impact certain cell adhesion proteins such as VE-cadherin 
(Guelte et al. 2012). It has been shown that SEMA3F-NRP2 interactions can inhibit the 
PI-3K activity via a mTORC2-dependent pathway thereby downregulating RhoA GTPase 
mediated stress fiber assembly (Nakayama et al. 2015). As described previously, the 
endothelial cell cytoskeleton’s interactions with the extracellular matrix through integrin-
rich focal adhesions is critical for maintaining EC barrier integrity. Disruption of this 
interaction has been reported to induce leaky microvessels (M. G. Lampugnani et al. 
1991). Negative regulation of RhoA has been shown to promote endothelial barrier 
restoration after permeability increases (Qiao, Huang, and Lum 2003; M. H. Wu 2005). 
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Besides directly affecting junction adhesion molecules, SEMA3F also inhibits decreases 
U87-MG VEGF expression at both a transcriptional and translational level (Nakayama et 
al. 2015). Interestingly, it’s been shown that inactivation of tumor suppressors can lead to 
VEGF overexpression in tumor cells (Neufeld et al. 1999). Therefore, the observed 
differences in tissue swelling could be result of changes in vessel permeability from 
changes in VEGF expression.  
 
SEMA3F’s role in regulating lymphatic function 
 Edema formation is a delicate balance of fluid and solute leakage balanced with 
lymphatic drainage. While SEMA3F has shown effects on vascular permeability, it 
would be remiss to ignore the possible effect of SEMA3F on the lymphatic vasculature.  
Future experiments will involve injecting Evans blue dye intradermally in SEMA3F-Ad 
infected mice during DTH and measuring the amount of dye drained over time thereby 
giving a more direct measurement of lymphatic drainage. NRP2, the high affinity 
receptor for SEMA3F, is expressed on not only vascular EC but also on lymphatic 
endothelial cells. This raises an interesting question as to the extent, if any, SEMA3F 
regulates lymphatic drainage during inflammation. Preliminary data using the DTH 
mouse model in lymphatic cell specific NRP2 knockout mouse did not show any 
significant differences in tissue swelling (data not shown). However, more research is 
underway to investigate SEMA3F as a lymphatic regulator. Interestingly, it has been 
shown in our DTH mouse model that VEGFR-3 is downregulated during acute 
inflammation (Huggenberger et al. 2011). Similar to VEGF-2, VEGFR-3 is also 
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potentiated by NRP2 and has been shown to be involved in lymphatic sprouting, 
lymphangiogenesis, and endothelial cell functions (Favier et al. 2006; Xu et al. 2010). 
Previous research, including from our lab, has identified SEMA3F as negative regulator 
of lymphangiogenesis in certain cancers (Doçi et al. 2015; F. Wu et al. 2011) and 
lymphatic growth during wound healing (Maruyama et al. 2008). Although there is 
lymphatic vessel growth in acute inflammation, the formation of new lymphatic vessels 
(lymphangiogenesis) is more present in chronic inflammation (Skobe et al. 2001). 
Nonetheless, SEMA3F’s role in cutaneous DTH acute inflammation could be involved in 
lymphatic EC inhibition through its NRP2-Plexin receptor. It is interesting to hypothesize 
that edema formation, in part, is regulated by SEMA3F’s effects on both vascular 
permeability and lymphatic drainage.  
Permeability effects of SEMA3A versus SEMA3F  
SEMA3A was the first semaphorin identified in vertebrates and, like the other 
class 3 semaphorins, is implicated in many physiological functions outside of nervous 
system (Kurschat et al. 2006; Yuling Luo, Raible, and Raper 1993; Okubo et al. 2011). 
Both SEMA3F and SEMA3A have anti-angiogenic potential and synergistic effects when 
bound to their respective receptors NRP2 and NRP1. It has been shown that SEMA3A 
inhibits PI3K thereby inducing growth cone collapse similar to SEMA3F (Gallo 2008) 
Interestingly, while SEMA3A and SEMA3F share some similar functions, SEMA3A has 
been shown to be a pro-permeability factor by many groups (Acevedo et al. 2008; Cerani 
et al. 2013; Guelte et al. 2012; Hou et al. 2015). Analyzing the mechanisms of 
SEMA3A’s effect on permeability may provide clues on our own investigation into 
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SEMA3F’s anti-permeability effects. Initially shown by Acevedo et al. (2008), SEMA3A 
induces vascular permeability independently of VEGF or integrins. However, SEMA3A 
seems to have cross-talk with parts of the VEGF pathway by suppressing FAK and Src 
phosphorylation, possibly through NRP1/Plexin downstream signaling. Addition of 
exogenous SEMA3A with VEGF-A additively induces vascular permeability by 
enhancing VE-cadherin phosphorylation through distinct pathways. Furthermore, they 
showed SEMA3F does not possess the same pro-permeability functions of SEMA3A 
(Figure 16). These papers taken together with our data, strongly reinforces our hypothesis 
that SEMA3F reduces vascular permeability. Given the opposing vascular permeability 
effects of SEMA3A & F, the relative concentrations of SEMA3F to SEMA3A might 
influence the degree of vascular permeability in the tissue microenvironment.  
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Figure 16 | Comparison of SEMA3A and SEMA3F’s permeability effects. A) In a 
Miles assay, addition of exogenous SEMA3A (30 μg/mL) with VEGF-A (40 μg/mL) 
recombinant protein subcutaneously induced higher levels of permeability than each 
agent alone. B) Unlike SEMA3A, SEMA3F does not induce permeability in a Miles 
assay. Data is represented as means ± SEM. Adapted from Acevedo et al. (2008). 
 
It has been suggested that in the presence of SEMA3A, VEGF can use alternative 
pathways to the known VEGF associated FAK/Src pathways to phosphorylate VE-
cadherin and disrupt adherens junctions (Acevedo et al. 2008). Since Acevedo et al. 
(2008), SEMA3A has been discovered to be a key initiator of vascular permeability 
within the neuronal retina in early hyperglycemic phases of diabetic retinopathy. Similar 
to SEMA3F, SEMA3A is endogenously expressed at basal levels but then becomes 
elevated during the early progression of the disease while VEGF levels remain low 
(Cerani et al. 2013). Similarly, SEMA3A is upregulated in the brain following cerebral 
ischemia. When recombinant SEMA3A is injected intradermally into mouse and the 
cerebral cortex, dose- and time-dependent increases in vascular permeability were 
observed. The mechanism is suggested to be SEMA3A binding to NRP1/VEGFR1 
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receptor complex activating Mical2, a F-actin modulator, which in turn induces 
cerebrovascular permeability (Hou et al. 2015). While SEMA3A has been shown to be 
able to bind NRP1, its affinity for NRP2 compared to SEMA3F is significantly lower 
(Antipenko et al. 2003; Fiore and Püschel 2003). In neurons, it has been shown that 
SEMA3A can affect the glycogen synthase kinase 3 beta pathway (GSK3B) (Uchida et 
al. 2005). GSK3B phosphorylation is shown to be important in maintaining lung 
endothelium integrity by increasing the availability of beta-catenin, a key molecule in 
maintaining endothelial adherens junction complex (Liu et al. 2002; Neumann et al. 
2013; Sawant et al. 2011). Furthermore, inhibition of GSK3B can cause an increase in 
endothelial permeability mediated by reactive oxygen/nitrogen species (Neumann et al. 
2013). Another group has shown that SEMA3A destabilizes the brain endothelial barrier 
integrity by disrupting the protective effect of the serine/threonine phosphatase PP2A 
(Guelte et al. 2012). PP2A is constitutively bound to VE-cadherin in quiescent 
endothelial cells, aiding in the maintenance of cystoskeletal integrity (Tar et al. 2004, 
2006). Upon SEMA3A stimulation, PP2A activity is inhibited, leading to eventual VE-
cadherin internalization and cell-cell junctional weakening leading to elevated levels of 
vascular permeability (Guelte et al. 2012). However, unlike Acevedo et al. (2008), they 
have discovered that this process is Src-dependent in brain endothelial cells.  
Atopic dermatitis is a type of chronic DTH reaction to endogenous antigens 
characterized by microvascular hyperpermeability, chronic inflammation, and vascular 
remodeling. (Tominaga, Ogawa, and Takamori 2008). Interestingly, studies have shown 
that SEMA3A is expressed in keratinocytes. (Chang et al. 2007; Fantini et al. 1995) 
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However, epidermal SEMA3A expression was reported to be downregulated in atopic 
dermatitis (Kubanov, Katunina, and Chikin 2015). It has been proposed that SEMA3A 
has a direct immunosuppressive role on T-cell activation and proliferation through NRP-
1 mediated actin cytoskeletal reorganization (Catalano 2010; Lepelletier et al. 2006). 
While permeability is desired for effective leukocyte infiltration, SEMA3A’s main role in 
cutaneous inflammation could be more important for more immune regulation. In this 
instance, SEMA3A is downregulated to allow for leukocyte infiltration and immune cell 
effector functions and then upregulated as immune cells are cleared from the site of 
injury.  
Unfortunately, there are currently no clinical trials studying the therapeutic use of 
class 3 semaphorins as drugs. However, SEMA3F could possess high therapeutic 
potential as an anti-inflammatory, anti-permeability factor. For instance, patients with 
diabetic retinopathy, where dysfunctions arise in the blood-retinal barrier, often present 
with diabetic macular edema correlated with increases in VEGF, which if left untreated 
can lead to vision loss. Perhaps SEMA3F could serve as a potential therapeutic 
intervention in the early stages of diabetic retinopathy, halting edema formation and 
disease progression. More broadly, exogenous SEMA3F addition can be an alternative or 
part of a combination treatment to enhance the current standard of care involving anti-
VEGF therapies.  
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